On November 10, Genmab A/S saw an Overnight rise of 5.68%, trading at $58.97. The move appeared to extend recent strength after investors continued to digest the company’s quarterly earnings beat and positive late-stage oncology trial updates.
Genmab A/S previously reported third-quarter earnings per share of $5.51, well above the $3.59 consensus estimate, while revenue was $1.187 billion versus the $1.194 billion estimate. The profit outperformance pointed to stronger-than-expected earnings delivery even as sales came in slightly below forecasts.
Pipeline developments remained an additional catalyst. The company said its phase 3 LiGeR-HN1 trial showed Petosemtamab plus pembrolizumab met both primary endpoints in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma, with the combination reducing the risk of death by 50% versus pembrolizumab alone. The company has said it plans to engage with regulators globally following the result.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)